DigitalDx Ventures

www.digitaldxventures.com

VCMatch tracks DigitalDx Ventures as an investor focused on AI/ML, Digital Health, and Healthtech companies, Seed and Series A rounds, United States and Silicon Valley markets, and $10k to $15m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$10k to $15m

Stages

Seed, Series A

Focus Areas

AI/ML, Digital Health, Healthtech

Geography

United States and Silicon Valley

Investment Thesis

DigitalDx Ventures invests at the intersection of AI, big data and healthcare diagnostics with the thesis that diagnostics — powered by machine learning and large biological datasets — is the largest emerging opportunity in personalized medicine. They target early-stage companies that improve diagnosis and treatment, create both outsized financial returns and measurable social impact, and use domain expertise and structured decision tools to systematically de-risk early-stage healthcare investments.

Is DigitalDx Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

DigitalDx Ventures is most relevant for founders raising Seed and Series A rounds in AI/ML, Digital Health, Healthtech, and Biotech, especially across United States and Silicon Valley, with public check-size signals around $10k to $15m.

Focus statement

DigitalDx Ventures is an early-stage, Silicon Valley venture fund "creating outsized financial and social impact by investing in early-stage health technology companies that deliver innovative solutions using artificial intelligence (AI) to better diagnose + treat illness." Their investments emphasize AI-enabled diagnostics that enable earlier, less-invasive, lower-cost and more accessible care.

Value Add

Proprietary investment decision model: the "Investment Tool for Expert Diagnostics (iTED)" to standardize evaluation and include social impact elements.
Deep, cross-disciplinary team with medical, scientific, AI, legal and venture experience (views "over 80 companies per month").
Majority woman-owned / gender-forward investing: "More than half of the DDx portfolio companies have women founders or women in the C-suite" and "50% of the Limited Partners in Fund 1 are women."
Operational experience in diagnostics commercialization (eg. early use of genomic testing and CLIA lab certification to deliver Laboratory Developed Tests).
Explicit impact measurement orientation: publicly shared impact approach and alignment with UN SDGs (Good Health & Well Being, Gender Equality).
Robust network: EIR program, advisory board including Nobel Prize-winning scientists and Fortune 100 executives, and ties to Stanford/UCSF and clinical testing institutions.
Clear product focus areas emphasized by the firm: "Enabling early, more accurate detection", "Minimizing invasiveness", and "Expanding access to treatment through lowered costs."